{"entity":{"id":"buserelin","kind":"drug","name":"Buserelin","aka":[],"tldr":"Buserelin is one of the original GnRH agonists, approved in Europe and Canada in the 1980s for advanced prostate cancer and also used in endometriosis and fertility treatment; it is not sold in the United States.","summary":"Buserelin, developed by Hoechst, was among the first GnRH agonists to reach the market and has been used since the mid-1980s in Europe, Canada and elsewhere for hormone-dependent advanced prostate cancer, given as a depot injection or nasal spray, with the same testosterone suppression and tumour flare as its class. Its wider use has been in endometriosis and in vitro fertilisation cycles. Goserelin, leuprolide and triptorelin displaced it in most oncology settings because of their longer depot formulations.","status":"established","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Buserelin","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Buserelin"},{"label":"ChEMBL CHEMBL1201248","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201248"}],"tags":["gap-fill","chembl-universe"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["endocrine-therapy"],"targets":["gnrhr"],"drugs":["leuprolide","goserelin","triptorelin"],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04513717","nct00567580","nct00936390"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Suprefact","modality":"GnRH agonist, injection or nasal spray","mechanism":"A GnRH analogue that after an initial stimulation desensitises pituitary GnRH receptors, shutting down gonadotrophin release and so testosterone or oestrogen production.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/buserelin/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"gnrhr","kind":"target","name":"GnRH receptor (GNRHR)","route":"/targets/gnrhr/"}],"drug":[{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/"},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"trial":[{"id":"nct00003653","kind":"trial","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","route":"/trials/nct00003653/"},{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/"},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/"},{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/"},{"id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/"}]}}